Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders

Pharmazie

Volumn 65, Issue 7, 2010, Pages 471-476

  Du, Bin ^a   Li, Xiao Tian ^a   Zhao, Ya ^a   A, You Mei ^a   Zhang, Zhen Zhong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; NANOPARTICLE;

ARTICLE; BIOAVAILABILITY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG STABILITY; FREEZE DRYING; IN VITRO STUDY; PARTICLE SIZE; POWDER; SCANNING ELECTRON MICROSCOPY; X RAY ANALYSIS; ZETA POTENTIAL;

CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; ESTRADIOL; FREEZE DRYING; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POWDERS; SOLUBILITY; SUSPENSIONS; ULTRASONICS; X-RAY DIFFRACTION;

EID: 77955403169     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9387     Document Type: Article

References (25)

1. Akers MJ (2002) Excipient-drug interactions in parenteral formulations. J Pharm Sci 91: 2283-2300.
2. Brick MC, Palmer HJ, Whitesides TH (2003) Formation of colloidal dispersions of organic materials in aqueous media by solvent shifting. Langmuir 19: 6367-6380.
3. Chingunpituk J (2007) Nanosuspension technology for drug delivery. Walailak J Sci Tech 4: 139-153.
4. Filippos K, Santipharp P, Yunhui W (2007) Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliver Rev 59: 631-644. (Pubitemid 47285408)
5. Floyd AG (1999) Top ten considerations in the development of parenteral emulsions. Pharm Sci Tech 4: 134-143.
6. Hany SM, Peter Y, Nicholas B (2009) Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 375: 107-113.
7. Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Lamer SL, Amighi K (2006) Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 64: 360-368.
8. James J, Murry DJ, Anthony M (2006) Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25: 41-48. (Pubitemid 44657641)
9. Kesisoglou F, Panmai S, Wu YH (2007) Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliver Rev 59: 631-644. (Pubitemid 47285408)
10. Lannibois H, Hasmy A, Botet R, B Chariol, Cabane B (1997) Surfactant limited aggregation of hydrophobic molecules in water. J Phys II France 7: 319-342. (Pubitemid 127807034)
11. Lawrence MJ, Rees GD (2000) Microemulsion-based media as novel drug delivery systems. Adv Drug Deliver Rev 45: 89-121.
12. Lindfors L, Forssen S, Skantze P, Skantze U, Zackrisson A, Olsson U (2006b) Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations. Langmuir 22: 911-916.
13. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U (2006a) Amorphous drug nanosuspensions, 1. Inhibition of ostwald ripening. Langmuir 22: 906-910.
14. Lipinski CA (2001) Avoiding investment in doomed drugs. Is poor solubility an industry wide problem? Curr Drug Discov 1: 17-19.
15. Lipinski C (2002) Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 5: 82-85.
16. Loftsson T, Brewster ME (1996) Pharmaceutical applications of cyclodextrins. J Pharm Sci 85: 1017-1025.
17. Muller RH, Peters K (1998) Nanosuspensions for the formulation of poorly soluble drugs: preparation by a size reduced technique. Int J Pharm 160: 229-237. (Pubitemid 28083096)
18. Nakano M (2000) Places of emulsions in drug delivery. Adv Drug Deliv Rev 45: 1-4.
19. Patravale VB, Date AA, Kulkarni RM (2004) Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56: 827-840.
20. Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796.
21. Sinswat P, Matteucci ME, Johnston KP, Williams III RO (2007) Dissolution rates and supersaturation behavior of amorphous repaglinide particles produced by controlled precipitation. J Biomed Nanotechnol 3: 18-27. (Pubitemid 351877124)
22. Srinivas G, James W, Paxton BC, Baguley SG (2009) Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 367: 179-186.
23. Stella VJ, Rajewski RA (1997) Cyclodextrins: their future in drug formulation and delivery. Pharm Res 14: 556-567. (Pubitemid 27220271)
24. Vitale SA, Katz JL (2003) Liquid droplet dispersions formed by homogeneous liquid-liquid nucleation: "The ouzo effect". Langmuir 19: 4105-4110.
25. Zhang X, Xia Q, Gu N (2006) Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm 32: 857-863. (Pubitemid 44266770)